Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PG5O
|
|||
| Drug Name |
Retifanlimab
|
|||
| Synonyms |
MGA012; INCMGA0012
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Approved | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 3 | [2] | ||
| Merkel cell carcinoma [ICD-11: 2C34; ICD-10: C44] | Phase 2 | [3] | ||
| Metastatic colorectal cancer [ICD-11: 2B91; ICD-10: C19] | Phase 2 | [4] | ||
| Penile squamous cancer [ICD-11: 2C81; ICD-9: 187] | Phase 1 | [5] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [6], [7] | ||
| Company |
Incyte
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | Inhibitor | [4], [7] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761334. | |||
| REF 2 | ClinicalTrials.gov (NCT04203511) INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301). U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT03599713) A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201). U.S. National Institutes of Health. | |||
| REF 4 | Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. | |||
| REF 5 | ClinicalTrials.gov (NCT04231981) Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) (ORPHEUS). U.S. National Institutes of Health. | |||
| REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 7 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.